Stockscreener 앱 받기
1.135
0.00%
0.005
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN
SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire
3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail
SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq
SELLAS reports promising DLBCL treatment trial results - Investing.com
SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq
SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle
SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News
Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News
SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel
Orangekloud Technology Inc (NASDAQ: ORKT) Up 58.11% From 52-Week Low; YTD Falls -50.99% – Here’s What To Do Now – Marketing Sentinel - Marketing Sentinel
Stock Traders Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - MarketBeat
Insider’s View: Deciphering SELLAS Life Sciences Group Inc (SLS)’s Financial Health Through Ratios - The Dwinnex
Market Analysts see SELLAS Life Sciences Group Inc [SLS] gaining to $18. Time to buy? - The DBT News
SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - Defense World
You Should Read This Analysis Before Investing in SELLAS Life Sciences Group Inc (NASDAQ:SLS) - US Post News
Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World
Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register
SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa
SELLAS secures $25 million in registered direct offering - MSN
SELLAS Life Sciences Group Announces $25 Million Registered - GlobeNewswire
Major Healthcare Investor Backs SELLAS with $25M DealHere's the Full Structure - StockTitan
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - Defense World
SELLAS Life Sciences Announces Positive Phase 3 Trial Results - TipRanks
SELLAS Life Sciences stock falls on GPS data (SLS:NASDAQ) - Seeking Alpha
SELLAS Life Sciences Announces Positive Outcome of Interim - GlobeNewswire
SELLAS Phase 3 AML Trial Shows Promising 13.5-Month Survival Data, Double Historical Average - StockTitan
Biotech CEO predicts 'revolutionary decade' in medicine through AI advancements - Fox News
SLS Stock Quote Price and Forecast - CNN
SELLAS Life Sciences amends executive severance agreements - MSN
SELLAS Life Sciences Group Inc (NASDAQ: SLS): Blank Check On Growth? - Stocks Register
SELLAS Life Sciences Group Approves Amendments to Change in Control Severance Agreements - Defense World
SELLAS Life Sciences amends executive severance agreements By Investing.com - Investing.com Australia
SELLAS Life Sciences Amends Severance for Key Executives - TipRanks
Analyze SELLAS Life Sciences Group Inc (NASDAQ: SLS) Before Investing. - Stocks Register
Geode Capital Management LLC Has $757,000 Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
SELLAS advances cancer drug trials, eyes key 2025 milestones - Investing.com
SELLAS advances cancer drug trials, eyes key 2025 milestones By Investing.com - Investing.com UK
0.90%
0.22%
자본화:
|
볼륨(24시간):